{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "marketState": "PRE", "exchange": "NCM", "regularMarketChangePercent": 0.8416971, "regularMarketPrice": 31.15, "firstTradeDateMilliseconds": 1272893400000, "priceHint": 2, "earningsTimestamp": 1682944200, "earningsTimestampStart": 1691411400, "earningsTimestampEnd": 1691757000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.13, "epsForward": -0.46, "epsCurrentYear": -1.04, "priceEpsCurrentYear": -29.951923, "sharesOutstanding": 149396000, "bookValue": 0.426, "fiftyDayAverage": 21.1053, "fiftyDayAverageChange": 10.044699, "fiftyDayAverageChangePercent": 0.4759325, "twoHundredDayAverage": 12.279425, "twoHundredDayAverageChange": 18.870575, "twoHundredDayAverageChangePercent": 1.5367638, "marketCap": 5241236480, "forwardPE": -67.71739, "priceToBook": 73.12206, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.2 - Buy", "tradeable": false, "cryptoTradeable": false, "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": 0.26000023, "regularMarketTime": 1684180805, "regularMarketDayHigh": 31.91, "regularMarketDayRange": "30.34 - 31.91", "regularMarketDayLow": 30.34, "regularMarketVolume": 3012738, "regularMarketPreviousClose": 30.89, "bid": 0.0, "ask": 0.0, "bidSize": 9, "askSize": 8, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 30.9, "averageDailyVolume3Month": 4433296, "averageDailyVolume10Day": 5422270, "fiftyTwoWeekLowChange": 27.67, "fiftyTwoWeekLowChangePercent": 7.9511495, "fiftyTwoWeekRange": "3.48 - 35.67", "fiftyTwoWeekHighChange": -4.5199986, "fiftyTwoWeekHighChangePercent": -0.12671709, "fiftyTwoWeekLow": 3.48, "fiftyTwoWeekHigh": 35.67, "displayName": "TG Therapeutics", "symbol": "TGTX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 226, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq.", "age": 56, "title": "Chairman, CEO & Pres", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 1968750, "fmt": "1.97M", "longFmt": "1,968,750"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 2465000, "fmt": "2.46M", "longFmt": "2,465,000"}}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA, CPA", "age": 40, "title": "CFO, Corp. Sec. & Treasurer", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": {"raw": 652600, "fmt": "652.6k", "longFmt": "652,600"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1398200, "fmt": "1.4M", "longFmt": "1,398,200"}}, {"maxAge": 1, "name": "Jenna  Bosco", "title": "Sr. VP of Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 3, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 5, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}